Transcranial Temporal Interference Stimulation In Severely Brain Injured Patients With Disorders of Consciousness
Launched by XIJING HOSPITAL · Feb 26, 2025
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a new treatment approach for patients who have severe brain injuries and are experiencing disorders of consciousness, such as Unresponsive Wakefulness Syndrome (UWS) or Minimally Conscious State (MCS). The study aims to see how a technique called transcranial temporal interference stimulation (tTIS), which is a noninvasive method that uses electrical signals, can affect brain activity in these patients. The goal is to better understand if this treatment can help improve awareness and response in individuals who are currently unable to communicate or interact with their environment.
To participate in the trial, patients must be between the ages of 6 and 74 and have a diagnosis of UWS or MCS due to a severe brain injury, either from an accident or other causes. However, individuals who are in a coma, have had their injury less than a week ago, or have certain medical devices like pacemakers are not eligible. If someone is part of this study, they can expect to undergo a safe, noninvasive procedure that may help researchers learn more about brain recovery. This trial is currently recruiting participants, so if you know someone who fits the criteria, they may have the opportunity to contribute to important research in this area.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • traumatic and nontraumatic etiology of VS/UWS or MCS according to published diagnostic criteria.
- Exclusion Criteria:
- • patients in coma, with less than 1 week after acute brain insult, with fluctuating diagnosis on baseline assessment, and with a metallic cerebral implant or pacemaker, and with epilepsy.
About Xijing Hospital
Xijing Hospital, a prominent medical institution affiliated with the Fourth Military Medical University in Xi'an, China, is dedicated to advancing healthcare through innovative clinical research. Renowned for its comprehensive range of medical services and expertise in various specialties, Xijing Hospital actively sponsors clinical trials aimed at evaluating new therapies, improving patient outcomes, and contributing to scientific knowledge. With a commitment to ethical standards and patient safety, the hospital fosters collaboration among multidisciplinary teams to drive forward the development of effective treatment options that address critical health challenges.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Xi'an, Shaanxi, China
Patients applied
Trial Officials
wen Jiang, phD
Principal Investigator
Xijing Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported